AMOEBA (EPA:ALMIB) - AMOEBA EXTENDS TO THE U.S.A. THE TESTING OF ITS BIOCONTROL PRODUCTS WITH THE US GROUP GOWAN COMPANY

Transparency directive : regulatory news

07/12/2020 17:45

PRESS RELEASE

AMOEBA EXTENDS TO THE U.S.A. THE TESTING OF ITS BIOCONTROL PRODUCTS WITH THE US
GROUP GOWAN COMPANY

Chassieu (France), December 7, 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating the risk in water and
human wounds, and of a biocontrol product for plant protection, still in the
testing phase, announces the signature of a Material Transfer Agreement (MTA)
with GOWAN COMPANY, a leading supplier of agricultural inputs (crop protection
products, seeds and fertilizers) in the USA.

The purpose of the research partnership is the provision by Amoéba of
experimental products containing the amoeba lysate Willaertia magna C2c Maky.
In return, GOWAN COMPANY will carry out its own field trials to evaluate the
performance of these products in preventing fungal diseases on a range of crops
in the US market.

Amoéba and GOWAN COMPANY are thus embarking on a targeted research phase,
which, if successful, could promote the commercial development of Amoéba
biocontrol solutions in the USA

"This research partnership with a US company generating more than $500M in
revenue materializes the first step in market engagement of Amoéba biocontrol
products. It's perfectly aligned with the current assessment of our biocontrol
dossier by the US authorities", explains Jean-Luc Souche - Amoéba Biocontrol
Business Developer.

About GOWAN COMPANY
Gowan Company, based in Yuma, Arizona, USA, is a family-owned developer,
registrant and marketer of crop protection products, seeds, and fertilizers.
Gowan champions technology for agriculture and horticulture through innovative
product development, public advocacy and quality production. Gowan's strong
commitment to biologicals stems from their steadfast dedication to
understanding and anticipating grower needs.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA EXTENDS TO THE U.S.A. THE TESTING OF ITS BIOCONTROL PRODUCTS WITH THE US GROUP GOWAN COMPANY

Transparency directive : regulatory news

AMOEBA's latest news

Other stories